RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing ...
A year of strategic execution concluded with a strong Q4 Fourth quarter 2025 (October - December) Total revenue amounted to SEK 65.6 (68.3) million, a decrease of SEK 2.7 million corresponding to 3.9% ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果